WHWKWhitehawk Therapeutics Inc.

Whitehawk Therapeutics Presents RealWorld Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 Whitehawk Therapeutics Presents RealWorld Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC...

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference PR Newswire MORRISTOWN, N.J., May 28, 2026 MORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc.(Nasdaq...

Whitehawk said it has secured rights from Hangzhou DAC to use the CPT113 linker-payload technology in up to five additional internally developed programs.

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload PR Newswire MORRISTOWN, N.J., May 21, 2026 Agreement with Hangzhou DAC Provides Option for Up...

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit PR Newswire MORRISTOWN, N.J., May 20, 2026 MORRISTOWN, N.J., May 20, 2026 /PRNewswire/ -- Whitehawk Therapeutics...

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum PR Newswire MORRISTOWN, N.J...

Risk appetite came roaring back and several companies standing out, as market participants rotated heavily into sectors tied to transformative technologies and high-growth macro trends. $TGNT, $QUCY, $AEHL, $TDIC, $WGRX, $ERNA, $SLS, $WHWK

Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing PR Newswire MORRISTOWN, N.J., May 13, 2026...

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) saw a significant growth in short interest in April. As of April 15th, there was short interest totaling 780,056 shares, a growth of 12.4% from the March 31st total of 693,909 shares. Currently, 3.3% of the shares of the stock are sold...